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This article reports a rapid response of intravitreal aﬂibercept for the treatment of a case of neovascular
age-related macular degeneration that developed tachyphylaxis to bevacizumab and ranibizumab. An
80-year-old man with neovascular age-related macular degeneration became unresponsive to monthly
treatment with bevacizumab or ranibizumab after initial responsiveness, to as-needed treatment with
these antivascular endothelial growth factor drugs for 49 months. Subretinal ﬂuid and pigment epithelial
detachment had sustained in spite of 14 bevacizumab and seven ranibizumab injections prior to intra-
vitreal aﬂibercept treatment. After only one injection of intravitreal aﬂibercept, a marked improvement
was seen within 1 week. Complete drying of subretinal ﬂuid and marked subsidence of pigment
epithelial detachment were noted 4 weeks after the ﬁrst aﬂibercept injection and sustained for three
consecutive monthly injections. This case reveals that shifting to aﬂibercept may be an effective alter-
native treatment for neovascular age-related macular degeneration that becomes tachyphylactic to
bevacizumab or ranibizumab.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Neovascular age-related macular degeneration (nAMD), char-
acterized by the formation of a choroidal neovascular membrane in
the macular area, is one of the greatest threats to vision in elderly
patients throughout the world, including those in Asia and Taiwan.
In recent years, intravitreal injections of antivascular endothelial
growth factor (anti-VEGF) agents have been used to treat nAMD. Of
these drugs, ranibizumab (Lucentis, Genentech, Inc., South San
Francisco, CA, USA) and bevacizumab (Avastin, Genentech, Inc.)
have been the most widely adopted anti-VEGF agents. Both bev-
acizumab and ranibizumab are humanized monoclonal antibodies
that target all forms of isomers of the VEGF-A family and the drugs
have been proved by numerous clinical studies to be highly effec-
tive treatment options for nAMD.e no conﬂicts of interest.
ology, Sing-Kong Wu Ho-Su
strict, Taipei, Taiwan.
.-K. Cheng).
e Ophthalmologic Society of TaiwAlthoughmost patients with typical nAMD respond favorably to
these anti-VEGF drugs, as clinical experience has increased over the
years it has been discovered that many patients become less
responsive to ranibizumab or bevacizumab after prolonged treat-
ment. One long-term unfavorable effect of particular note is
tachyphylaxis, which is deﬁned as a progressively decreased ther-
apeutic response to a drug after repeated administration over
time.1 Tachyphylaxis has been demonstrated in both bevacizumab
and ranibizumab for the treatment of nAMD.2e5 In a retrospective
review of 1027 eyes (976 patients) with a mean follow-up time of
24 (range 13e37) months, the percentage of eyes with tachyphy-
laxis to ranibizumab was approximately 2%.2 In another, relatively
smaller study, tachyphylaxis to bevacizumab was found in six of 58
eyes with nAMD treated with bevacizumab.3 The median time for
developing tachyphylaxis was found to be 100 weeks from the ﬁrst
treatment of bevacizumab.3
Aﬂibercept (Eylea, Regeneron, Tarrytown, PA, USA and Bayer
HealthCare, Berlin, Germany) is new member of pharmacotherapy
targeting VEGF-A family that was approved for the treatment of
nAMD by the Food and Drug Administration in November, 2011.
Several large-scale randomized clinical trials have proved thatan. Published by Elsevier Taiwan LLC. All rights reserved.
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nAMD.6 Unlike bevacizumab or ranibizumab, the structure of aﬂi-
bercept is not an antibody; rather, it is composed of a recombinant
soluble decoy receptor fusion protein which incorporates the sec-
ond binding domain of the VEGF receptor-1 and the third binding
domain of the VEGF receptor-2.7 The binding afﬁnity of intravitreal
aﬂibercept to VEGF was shown to be higher than that of ranibizu-
mab.7 Studies have suggested that aﬂibercept may be effective in
treating patients with chronic refractory nAMD and persistent ﬂuid
despite repeated treatments of intravitreal ranibizumab and/or
bevacizumab.8e11 Patel et al12 further reported rapid resolution of
pigment epithelial defect (PED) in three patients with neovascular
AMD refractory to ranibizumab and bevacizumab.
In this report, we present here the case that developed
tachyphylaxis with persistent subretinal ﬂuid (SRF) and PED to
monthly injections of bevacizumab or ranibizumab for 14
months. A rapid response with resolution of SRF and a marked
decrease in the size of PED was noted 1 week after changing to
intravitreal aﬂibercept injections and was maintained after three
consecutive monthly injections. To date, few reports concerning
aﬂibercept treatment of tachyphylaxis in nAMD have been made,
which is why we believe that this experience is worth sharing
with our colleagues.Fig. 1. (A) Photographs of color fundus showed drusen and retinal pigment epithelium (RPE)
pigment epithelial detachment were found in the left eye. (C) Fluorescein accumulation wa
found in the late ﬁlm. There was no polyp found on indocyanine green angiography (ICG)2. Case report
An 80-year-old Taiwanese man of Chinese descent complained
of bilateral blurred vision andmetamorphopsia for 5 months which
did not improve, even after an uneventful phacoemulsiﬁcation and
intraocular lens implantation for his cataract. On presentation, his
best corrected visual acuity was 6/30 od and 6/15 os. Fundus
photography (Fig. 1A and B) and ﬂuorescein angiography showed a
classic choroidal neovascularization in both eyes; no polyp was
found on indocyanine green angiography (Fig. 1E and F).
Both of the patient’s eyes were treated with intravitreal bev-
acizumab (2.5 mg in 0.1 mL; Avastin). The right eye responded
favorably with subsidence of SRF and intraretinal cysts. Although
several recurrences were encountered in his right eye during the
follow-up period, the exudative reaction responded favorably each
time after intravitreal bevacizumab injection. However, the left eye
did not always respond favorably to intravitreal bevacizumab. The
patient’s left eye received intravitreal bevacizumab (2.5 mg in
0.1 mL; Avastin) six times from April 6, 2010 to March 11, 2011 as
protocol. A good response with nearly total absorption of SRF was
noted following the ﬁrst three injections (monthly injections)
(Fig. 2A and B); however, SRF and PED sustained during the subse-
quent injections (Fig. 2C). He subsequently received four intravitrealdegeneration in the patient’s right eye. (B) Retinal hemorrhage and subretinal ﬂuid and
s noted in the early ﬁlm of ﬂuorescein angiography in the left eye and (D) leakage was
either early (E) or late (F) ﬁlm.
Fig. 2. Optical coherence tomography of the left eye during treatment. (A) SRF accumulation and PED were found before initiating treatment. (B) SRF subsided, yet persistent PED
was noted 1 week after the third intravitreal injection of bevacizumab. (C) SRF increased gradually and PED persisted following six injections of bevacizumab. (D) Remission of SRF
was noted after three injections of ranibizumab, but PED was still noted. PED ¼ pigment epithelial detachment; SRF ¼ subretinal ﬂuid.
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good response was noted once again following the ﬁrst three in-
jections (Fig. 2D); however, the fourth injection was unsuccessful.
As the SRF and PED persisted and his visual acuity decreased, we
shifted back to bevacizumab on December 30, 2011 and again on
March 2, 2012. However, the patient did not respond to the treat-
ment and SRF increased prominently after the second injection. We
subsequently arranged another course of three monthly injections
of ranibizumab from May 11, 2012 to September 8, 2012, but the
patient showed no signs of response whatsoever.
Due to sustained SRF and PED, we once again attempted an
intravitreal injection of bevacizumab from October 26, 2012 to MayFig. 3. (A) Fundus picture after 14 injections of bevacizumab and seven injections of ranibi
angiography in the left eye. (C) Prominent SRF and persistent PED were noted on optical coh
injection of aﬂibercept. (E) SRF regressed completely and PED became almost complete
SRF ¼ subretinal ﬂuid.8, 2013 (a total of six injections). The patient responded poorly to
bevacizumab and was found to have increased SRF and PED despite
monthly treatments (Fig. 3C). His visual acuity gradually
deteriorated.
At this time, aﬂibercept became available for a premarketing
trial in Taiwan and we ﬁled a clinical trial application for this pa-
tient. After obtaining informed consent from the patient and a
permit from the institutional review board of Shin Kong Wu Ho-Su
Memorial Hospital and the Taiwanese government’s Ministry of
Health and Welfare, we began injections of 2 mg of aﬂibercept
intravitreally to the left eye of the patient. The SRF and PED
dramatically decreased 1 week after the ﬁrst intravitreal injectionzumab. (B) Stippled hyperﬂuorescence with leakage was still noted on late ﬂuorescein
erence tomography. (D) Both SRF and PED decreased dramatically 1 week after the ﬁrst
ly ﬂat 3 months after the initial injection. PED ¼ pigment epithelial detachment;
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three times. The SRF became completely dry and the PED became
almost completely ﬂat 1 month after the third injection (Fig. 3E).
The best-corrected visual acuity also improved from 6/36 to 6/18
after 3 months of treatment with aﬂibercept.
3. Discussion
Our report clearly shows the immediate efﬁcacy of changing to
intravitreal aﬂibercept for the treatment of a Taiwanese patient
with nAMD who had developed tachyphylaxis to bevacizumab and
ranibizumab. The left eye of our patient initially showed subsidence
of SRF and improvement in macular edema after three monthly
injections of bevacizumab. However, the subsequent recurrence of
SRF and macular edema became refractory to a subsequent 11 in-
jections of intravitreal bevacizumab. Again, the patient initially
responded after being transferred to intravitreal ranibizumab for
three injections, but again became refractory to another subse-
quent four injections. However, after changing to treatment with
aﬂibercept, the SRF that had persisted for over 14 months rapidly
regressed within 1 week and became completely dry in 4 weeks. In
addition, the prominent PED that persisted from the beginning of
treatment with bevacizumab or ranibizumab also became mark-
edly decreased within 1e4 weeks after intravitreal aﬂibercept
injection.
Several other studies have shown the ability of aﬂibercept to
decrease SRF or intraretinal ﬂuid in eyes with nAMD which were
refractory to intravitreal ranibizumab or bevacizumab. Cho et al9
reported that, in 28 eyes with persistent SRF after repeated and
regular intravitreal ranibizumab or bevacizumab, or both, in-
jections (mean 20 injections, range 7e37), 89% (25 eyes) showed
anatomical improvement and 18% (5 eyes) were dry at 1 month
after a single aﬂibercept injection. The central subfoveal thickness
signiﬁcantly improved (p < 0.001) from 295 to 272 microns after
one aﬂibercept injection and remained improved (274 microns,
p ¼ 0.008) after an average of 4.4 aﬂibercept injections (range 3e6)
over 6 months. At the end of 6 months, 64% (18 eyes) showed
anatomical improvement and 25% (seven eyes) were dry.
In another study of 68 eyes with nAMD that were refractory to
ranibizumab or bevacizumab, or both, Yonekawa et al11 also re-
ported a signiﬁcant decrease in central macular thickness, SRF, and
intraretinal ﬂuid after conversion to aﬂibercept for both the ﬁrst
and ﬁnal injections (mean 3.8 injections, mean follow-up time 18
weeks). These workers suggested that the enhanced anatomical
response seen with aﬂibercept in their previously treated patients
may represent a stronger clinical activity of aﬂibercept or tachy-
phylaxis to the earlier long-term treatments.
PED, an anatomical feature that was regarded to be less
responsive than SRF or intraretinal ﬂuid to ranibizumab and bev-
acizumab,13,14 has also been reported to respond favorably to aﬂi-
bercept.10,12 In a retrospective study of 34 eyes with nAMD (33
patients) with persistent subfoveal ﬂuid despite previous treat-
ment with ranibizumab, Kumar et al10 found that, after changing to
treatment with aﬂibercept, not only the SRF and intraretinal ﬂuid
signiﬁcantly subsided, but also the height and diameter of the PED
signiﬁcantly decreased at the 6-month follow-up. In their report,
the mean visual acuity was also signiﬁcantly improved at the 6-
month follow-up. The case reported here also showed a marked
subsidence of previously prominent PED beginning 1 week after
the ﬁrst treatment with aﬂibercept, which remained nearly ﬂat
over the course of three subsequent monthly injections. The best-
corrected visual acuity of our patient gradually improved from 6/
36 to 6/18 after three consecutive monthly injections.
Aﬂibercept has been suggested to have higher biological activity
to neutralize the effect of VEGF than ranibizumab andbevacizumab.7,15 An in vitro study conducted by Papadopoulos et al7
showed that aﬂibercept had 94 and 119 times the binding afﬁnity to
VEGF-A165 of ranibizumab and bevacizumab, respectively. Aﬂi-
bercept has also been shown to possess not only an anti-VEGF ef-
fect, but also an antiplacental growth factor effect; the latter is
known to be an important factor in facilitating angiogenesis.16
These characteristics could be a contributing factor which enables
aﬂibercept to treat eyes with nAMDwhich were either refractory or
becoming tachyphylactic to ranibizumab or bevacizumab.
Themechanismof tachyphylaxis to bevacizumabor ranibizumab
as it relates to the treatment of nAMD remains unclear. Proposed
mechanisms2 include the formationof neutralizing antibodies to the
anti-VEGFdrugs,17 thedesensitizationof the target tissue to thedrug
(possibly caused by the upregulation of the production of VEGF by
macrophages in the tissue of choroidal neovascularization),18,19 or
the possibility that choroidal neovascularization is reactivated by
other growth factors and pathways.20,21 Sometimes simply switch-
ing to a similar drug with different properties may be sufﬁcient to
overcome tachyphylaxis.1 For example, several retrospective studies
have suggested that shifting from bevacizumab to ranibizumab or
vice versa may be enough to resume the efﬁcacy of treatment for
nAMD after a patient develops tachyphylaxis.22,23 Therefore it re-
mains uncertain whether aﬂibercept is superior to the other anti-
VEGF drugs in the treatment of nAMD and further investigations
should be conducted.
In summary, our case shows a rapid response of aﬂibercept
treatment for nAMD with tachyphylaxis to both ranibizumab and
bevacizumab in a Taiwanese patient of Chinese descent. This report
is probably the ﬁrst clinical experience of such a condition in a
patient of Chinese descent in Taiwan and suggests that use of aﬂi-
bercept to treat nAMD which has become unresponsive to other
anti-VEGFs could be a promising treatment strategy.
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